Standout Papers

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults 2011 2026 2016 2021 3.1k
  1. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (2013)
    Michael D. Jensen, Donna H. Ryan et al. Journal of the American College of Cardiology
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)
    John Wilding, Rachel L. Batterham et al. New England Journal of Medicine
  3. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (2013)
    Michael D. Jensen, Donna H. Ryan et al. Circulation
  4. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk (2013)
    Robert H. Eckel, John M. Jakicic et al. Circulation
  5. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes (2011)
    Rena R. Wing, Wei Lang et al. Diabetes Care
  6. Mechanisms, Pathophysiology, and Management of Obesity (2017)
    Steven B. Heymsfield, Thomas A. Wadden New England Journal of Medicine
  7. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk (2013)
    Robert H. Eckel, John M. Jakicic et al. Journal of the American College of Cardiology
  8. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (2021)
    Melanie J. Davies, Louise Færch et al. The Lancet
  9. The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It (2006)
    Thomas A. Wadden, Delia Smith West et al. Obesity
  10. Binge eating disorder: Its further validation in a multisite study (1993)
    Robert L. Spitzer, Susan Z. Yanovski et al. International Journal of Eating Disorders
  11. Binge eating disorder: A multisite field trial of the diagnostic criteria (1992)
    Robert L. Spitzer, Michael J. Devlin et al. International Journal of Eating Disorders
  12. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (2021)
    Thomas A. Wadden, Timothy S. Bailey et al. JAMA
  13. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study (2013)
    Thomas A. Wadden, Priscilla Hollander et al. International Journal of Obesity
  14. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity (2005)
    Thomas A. Wadden, Robert I. Berkowitz et al. New England Journal of Medicine
  15. The Science of Obesity Management: An Endocrine Society Scientific Statement (2018)
    George A. Bray, Ashkan Afshin et al. Endocrine Reviews
  16. Primary Care Physicians’ Attitudes about Obesity and Its Treatment (2003)
    Gary D. Foster, Thomas A. Wadden et al. Obesity Research
  17. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022)
    John Wilding, Rachel L. Batterham et al. Diabetes Obesity and Metabolism
  18. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (2022)
    W. Timothy Garvey, Rachel L. Batterham et al. Nature Medicine
  19. Lifestyle Modification for Obesity (2012)
    Thomas A. Wadden, Victoria L. Webb et al. Circulation
  20. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial (2016)
    Adam Blackman, Gary D. Foster et al. International Journal of Obesity
  21. Lifestyle modification approaches for the treatment of obesity in adults. (2020)
    Thomas A. Wadden, Jena Shaw Tronieri et al. American Psychologist
  22. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial (2023)
    Thomas A. Wadden, Ariana M. Chao et al. Nature Medicine
  23. Dietary interventions for obesity: clinical and mechanistic findings (2021)
    Ariana M. Chao, Thomas A. Wadden et al. Journal of Clinical Investigation
  24. Nutritional considerations with antiobesity medications (2024)
    Jaime P. Almandoz, Thomas A. Wadden et al. Obesity
  25. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (2025)
    W. Timothy Garvey, Matthias Blüher et al. New England Journal of Medicine

Immediate Impact

2 by Nobel laureates 12 from Science/Nature 233 standout
Sub-graph 1 of 16

Citing Papers

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
24 intermediate papers

Works of Thomas A. Wadden being referenced

Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
2021 Standout
and 27 more

Author Peers

Author Last Decade Papers Cites
Thomas A. Wadden 14465 11087 15789 13722 447 47.3k
Rena R. Wing 15853 8828 15264 19740 640 47.6k
Jack A. Yanovski 8421 4125 7785 10099 423 30.2k
James O. Hill 6654 3903 18027 17347 409 39.0k
Donna H. Ryan 3105 3420 9717 6955 243 23.7k
John M. Jakicic 4217 2820 12927 9623 316 27.0k
Arne Astrup 3266 1316 24207 14996 815 49.3k
Jacob C. Seidell 2515 3095 12189 14399 491 35.8k
William C. Knowler 1470 3446 13972 9656 516 56.0k
Lars Sjöström 2373 3520 12201 3802 237 27.7k
Robert F. Kushner 1821 3256 9096 4000 213 21.5k

All Works

Loading papers...

Rankless by CCL
2026